CliffBio
biologic

AMTAGVI

Lifileucel

Loss of exclusivityFebruary 2036FDA regulatory exclusivity expiry
CompanyIovance Biotherapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMTAGVI
Active ingredientLifileucel
Strength7.5x10^9 to 72x10^9Cells
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

AMTAGVI patent cliff — loss of exclusivity February 2036 | CliffBio